Takeda is a research-based global company with its main focus on pharmaceuticals.
Ethical drugs are Takeda's core business, constituting about 81.5% of total net sales. Our two research centers in Japan conduct basic and applied research to create new breakthrough drugs. Development operations in Japan, the U.S. and Europe then work to move these drugs swiftly through development so that better treatments can be delivered as early as possible to patients around the world.
Takeda has an international marketing network including Japan and 13 overseas bases in the U.S., Europe and Asia. From these bases, Takeda markets its original products such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot®, Enantone®, Prostap® and Leuplin®), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid®, Ogast®, Takepron® and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress®, Kenzen® and Amias®) and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos®). Including sales through licensees, Takeda's pharmaceuticals are available in over 100 countries worldwide.
Our production network includes the Hikari, Osaka and Shonan plants in Japan, as well as Takeda Ireland Ltd., which was newly established in 1997 and manufactures drugs for the European and U.S. markets. In addition, Takeda has two production facilities in Asia.
In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drug market, in which we now hold the number-two domestic share. The increasing emphasis on self-medication among Japanese consumers should help drive further growth in this field. By taking the viewpoint of consumers, we provide products and services that are closely matched to consumer needs.
Our main brands in the Consumer Healthcare segment are well recognized among Japanese consumers and include Alinamin® (vitamin B1 derivative preparations, etc.), Benza® (cold remedies), Hicee® (vitamin C preparations).
On April 1,2005,Takeda transfered its life-environment business to Osaka Gas Chemicals Co., Ltd.
On April 1,2003,Takeda established a fully owned subsidiary Japan Enviro Chemicals,Ltd.
On November 1,2002,Takeda and Sumitomo Chemical Co.,Ltd. established a joint venture Sumitomo Chemical Takeda Agro Company by merging agrochemical business.
On April 1, 2002, Takeda and Kirin Brewery Company, Ltd. established a joint venture Takeda Kirin Foods Corporation by merging food business.
On April 1, 2001, Takeda and Mitsui Chemicals, Inc. established a joint venture Mitsui Takeda Chemicals, Inc. by merging two parties' urethane chemicals and composite materials businesses.
Bulk vitamin business
On Janyary 4, 2001, Takeda and BASF Japan Ltd. established a joint venture BASF Takeda Vitamins K.K.. On January 4, 2001, Takeda transferred all the shares of the following subsidiaries to BASF: Takeda Vitamin & Food USA, Inc., Takeda Canada Vitamin and Food Inc., Takeda Europe GmbH, and Takeda Vitamin & Food Asia Pte. Ltd.
Animal health business
On June 30, 2000, Takeda transferred its animal health business to a newly established joint venture, Takeda Schering-Plough Animal Health K.K.
Takeda in China
Takeda Pharmaceuticals (Tianjin) Co., Ltd. was set up in 1996 by joint venture of Takeda Pharmaceutical Company Limited and Tianjin Lisheng Pharmaceutical Co.Ltd.
The total investment of the company is USD 26.2 million with more than 300 employees.
Takeda has ten offices in China to cover the Chinese market.